You are here: Industry Insights > psoriasis

News List

Lipidor AB licence agreement grants Menarini Group company, RELIFE Srl, exclusive rights to register, promote, distribute and market two new psoriasis drug candidates for potential value of MEUR 70 prnasia
July 02, 2021
Lipidor AB (publ) announced today that it has signed a licence agreement under which Lipidor grants RELIFE S.r.l., part of leading international pharmaceutical company, Menarini Group, exclusive rights to register, promote, distribute, and market drug ...
Lipidor licence agreement grants Menarini Group company, RELIFE Srl, exclusive rights to register, promote, distribute and market two new psoriasis drug candidates for potential value of MEUR 70 firstwordpharma
July 02, 2021
Lipidor AB (publ) announced today that it has signed a licence agreement under which Lipidor grants RELIFE S.r.l., part of leading international pharmaceutical company, Menarini Group, exclusive rights to register, promote, distribute, and market drug.
Sonelokimab shows promise in Phase II psoriasis trial europeanpharmaceuticalreview
May 08, 2021
In the trial, 57 percent of patients with moderate to severe psoriasis treated with 120mg of sonelokimab achieved total skin clearance in 24 weeks.
BMS’ deucravacitinib tops Otezla in two psoriasis studies pharmatimes
April 27, 2021
Bristol Myers Squibb’s investigational selective tyrosine kinase 2 (TYK2) inhibitor deucravacitinib topped Amgen’s Otezla in two Phase III psoriasis studies.
Lipidor - update on the company's phase III clinical trial of drug candidate AKP02 for treatment of psoriasis prnasia
April 23, 2021
Lipidor AB (publ) provides an update on the planned Phase III study of the company's drug candidate AKP02 for the treatment of psoriasis. During the first quarter of 2021, Lipidor submitted an application to the Indian Medical Products Agency for ...
BMS’ deucravacitinib beats Otezla in psoriasis study pharmatimes
February 05, 2021
Bristol Myers Squibb’s investigative drug deucravacitinib has demonstrated positive results in a Phase III trial, including showing superiority over Amgen’s Otezla (apremilast).
IPC Statement On SARS-CoV-2 Vaccines And Psoriasis prnasia
December 03, 2020
The SARS-CoV-2 pandemic continues to have a considerable impact on the provision of appropriate care to people with psoriasis.
Bristol Myers Squibb’s psoriasis med hits the mark in phase III pharmatimes
November 06, 2020
Bristol Myers Squibb’s tyrosine kinase 2 (TYK2) inhibitor deucravacitinib outperformed Amgen’s Otezla in a phase III psoriasis study, the pharma company revealed yesterday.
FDA and EMA accept regulatory submissions for UCB’s bimekizumab pharmatimes
September 27, 2020
The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both accepted marketing application submissions for UCB’s psoriasis treatment bimekizumab.
FDA Approves STELARA for Pediatric Patients with Moderate to Severe Plaque Psoriasis americanpharmaceuticalreview
August 11, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for STELARA® (ustekinumab) as a treatment for pediatric patients (6-11 years of age) with the skin les

Previous page 1 2 3 4 5 6 7 8 9 10 Next page